Literature DB >> 2015043

A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease.

M M Simon1, U E Schaible, R Wallich, M D Kramer.   

Abstract

Lyme disease is the most common vector-transmitted illness in the USA and Europe. The pathogen, Borrelia burgdorferi, causes a complex spectrum of disease that affects the skin, joints, nervous system and heart. Patients in the early stages of the disease can often be successfully treated with antibiotics but this becomes less reliable as the disease progresses. The specific immune responses that are detectable in patients with Lyme disease are not sufficient to protect against illness; a vaccine against the infectious agent is, therefore, desirable. In this article Markus M. Simon and colleagues present a mouse model of Borrelia burgdorferi infection. Their work suggests that the outer surface protein A (OspA) of Borrelia burgdorferi may be a suitable vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015043     DOI: 10.1016/0167-5699(91)90106-4

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  24 in total

Review 1.  Lyme disease in paediatrics.

Authors:  B Cryan; D J Wright
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

Review 2.  The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.

Authors:  R Wallich; M D Kramer; M M Simon
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

3.  Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells.

Authors:  T R Rhinehart-Jones; A H Fortier; K L Elkins
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

4.  Molecular cloning and immunological characterization of a novel linear-plasmid-encoded gene, pG, of Borrelia burgdorferi expressed only in vivo.

Authors:  R Wallich; C Brenner; M D Kramer; M M Simon
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

Authors:  Y F Chang; M J Appel; R H Jacobson; S J Shin; P Harpending; R Straubinger; L A Patrican; H Mohammed; B A Summers
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Molecular and immunological characterization of a novel polymorphic lipoprotein of Borrelia burgdorferi.

Authors:  R Wallich; M M Simon; H Hofmann; S E Moter; U E Schaible; M D Kramer
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies.

Authors:  M Scriba; J S Ebrahim; T Schlott; H Eiffert
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

8.  Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, fla, HSP60, and HSP70 gene probes.

Authors:  R Wallich; C Helmes; U E Schaible; Y Lobet; S E Moter; M D Kramer; M M Simon
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.

Authors:  W S Probert; R B LeFebvre
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi.

Authors:  R K Straubinger; Y F Chang; R H Jacobson; M J Appel
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.